1.00Open0.48Pre Close40 Volume29 Open Interest20.00Strike Price7.34KTurnover95.78%IV10.84%PremiumDec 20, 2024Expiry Date0.30Intrinsic Value100Multiplier26DDays to Expiry2.20Extrinsic Value100Contract SizeAmericanOptions Type0.5784Delta0.0756Gamma9.12Leverage Ratio-0.0407Theta0.0067Rho5.28Eff Leverage0.0211Vega
Neurogene Stock Discussion
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet